<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04462003</url>
  </required_header>
  <id_info>
    <org_study_id>Apixaban in DVT with cancer</org_study_id>
    <nct_id>NCT04462003</nct_id>
  </id_info>
  <brief_title>Efficacy of Apixaban in Malignancy With Deep Venous Thrombosis</brief_title>
  <acronym>DVT</acronym>
  <official_title>Efficacy and Safety of Apixaban in Patients With Active Malignancy and Acute Deep Venous Thrombosis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beni-Suef University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beni-Suef University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of study was to evaluate the efficacy and safety of Apixaban in patients with acute
      deep venous thrombosis and active malignancy compared with weight adjusted subcutaneous
      (LMWH). It was hypothesised that Apixaban could be as effective as rivaroxiban and edoxaban
      in treatment of patients with acute DVT and active malignancy with a lower risk of bleeding
      especially in those with GIT cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with active malignancy have hypercoagulable state particularly, those receiving
      intravenous chemotherapy, with six fold higher risk of venous thromboembolism (VTE) [1].
      Anticoagulation for malignancy associated deep venous thrombosis (DVT) can be difficult
      because of different limitations like bleeding, drug-drug interactions with chemotherapy and
      inconvenience with repeated subcutaneous injections of low-molecular-weight heparin (LMWH)
      [2]. In comparison with patients without active malignancy, patients with cancer who are on
      warfarin therapy have 2 to 6 folds more major bleeding events and 2 to 3 times more VTE
      recurrence [3,4]. The American College of Chest Physicians Guidelines recommended (LMWH) as
      standard therapy for management of acute VTE in patients with active malignancy [5].
      Recently, Rivaroxiban and Edoxaban were considered as an alternative to weight-adjusted
      subcutaneous LMWH after pulmonary embolism in patients with active cancer without
      gastrointestinal (GIT) malignancy [6]. Apixaban is a direct factor Xa inhibitor approved by
      FDA for treatment of DVT and VTE [7]. However its efficacy in management of acute DVT and VTE
      associated with cancer is still unresolved issue. The aim of study was to evaluate the
      efficacy and safety of Apixaban in patients with acute deep venous thrombosis and active
      malignancy compared with weight adjusted subcutaneous (LMWH).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 3, 2019</start_date>
  <completion_date type="Anticipated">July 3, 2020</completion_date>
  <primary_completion_date type="Anticipated">July 2, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>Single blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Recurrent deep venous thrombosis or venous thromboembolism</measure>
    <time_frame>6 months</time_frame>
    <description>New or non resolving completely occluded deep venous thrombosis or occurrence of pulmonary embolism</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of fatal or major bleeding</measure>
    <time_frame>6 months</time_frame>
    <description>Need for hospitalization, blood transfusion, surgical intervention or resulting into death</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mortality related to massive pulmonary embolism</measure>
    <time_frame>6 months</time_frame>
    <description>Death caused by hemodynamic instability secondary to massive pulmonary embolism</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Occurrence of non-fatal or minor bleeding</measure>
    <time_frame>6 months</time_frame>
    <description>Bleeding that does not need hospitalization, blood transfusion, surgical intervention or resulting into death</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Deep Vein Thrombosis</condition>
  <condition>Malignancy</condition>
  <arm_group>
    <arm_group_label>Apixaban</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>50 patients with DVT with malignancy were randomized to apixaban 10 mg twice daily dose for 7 days followed by apixaban 5 mg twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Enoxaparin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>50 patients with DVT with malignancy were randomized to enoxaparin (1mg/Kg/SC every 12 h)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apixaban</intervention_name>
    <description>10 mg/12 h for 1 week followed by 5 mg/12 h</description>
    <arm_group_label>Apixaban</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enoxaparin</intervention_name>
    <description>1mg/Kg/sc/12h</description>
    <arm_group_label>Enoxaparin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria Patients with active malignancy presenting with acute deep venous
        thrombosis and still treated with chemotherapy

        Exclusion Criteria:

          -  Patients with pulmonary embolism and hemodynamic instability requiring thrombolytic
             therapy

          -  Previous DVT or venous thromboembolism

          -  Administration of LMWH or unfractionated heparin before randomization

          -  Brain tumours, cerebral metastes, hepatic tumours or impairment Child-Pugh B or C,
             -Recent or current active or life threating bleeding (e.g. intr acranial haemorrhage
             or gastrointestinal bleeding)

          -  Thrombocytopenia (platelets &lt;100 x 109L)

          -  Severe chronic kidney disease (estimated glomerular filtration rate &lt;30 ml/minute)

          -  Pregnant women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mostafa E Mokadem</last_name>
    <role>Principal Investigator</role>
    <affiliation>Faculty of Medicine, Beni-Suef University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mostafa O Mokadem</last_name>
    <phone>00201009414408</phone>
    <email>mostafa.elmokadem9@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Abd el aziz Z Algaby</last_name>
    <phone>00201227563870</phone>
    <email>zizogaby@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Faculty of Medicine,Beni-Suef University</name>
      <address>
        <city>Banī Suwayf</city>
        <state>Beni-Suef</state>
        <zip>62511</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mostafa O Mokadem</last_name>
      <phone>00201009414408</phone>
      <email>mostafa.elmokadem9@gmail.com</email>
    </contact>
    <contact_backup>
      <phone_ext>Mokadem</phone_ext>
      <email>mostafa.elmokadem9@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Mostafa O Mokadem</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Abd el aziz Z Algaby</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ahmed H Shaaban</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <results_reference>
    <citation>Heit JA, Silverstein MD, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ 3rd. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med. 2000 Mar 27;160(6):809-15.</citation>
    <PMID>10737280</PMID>
  </results_reference>
  <results_reference>
    <citation>Ay C, Beyer-Westendorf J, Pabinger I. Treatment of cancer-associated venous thromboembolism in the age of direct oral anticoagulants. Ann Oncol. 2019 Jun 1;30(6):897-907. doi: 10.1093/annonc/mdz111.</citation>
    <PMID>30918939</PMID>
  </results_reference>
  <results_reference>
    <citation>Hutten BA, Prins MH, Gent M, Ginsberg J, Tijssen JG, Büller HR. Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. J Clin Oncol. 2000 Sep;18(17):3078-83.</citation>
    <PMID>10963635</PMID>
  </results_reference>
  <results_reference>
    <citation>Prandoni P, Lensing AW, Piccioli A, Bernardi E, Simioni P, Girolami B, Marchiori A, Sabbion P, Prins MH, Noventa F, Girolami A. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood. 2002 Nov 15;100(10):3484-8. Epub 2002 Jul 12.</citation>
    <PMID>12393647</PMID>
  </results_reference>
  <results_reference>
    <citation>Kearon C, Akl EA, Ornelas J, Blaivas A, Jimenez D, Bounameaux H, Huisman M, King CS, Morris TA, Sood N, Stevens SM, Vintch JRE, Wells P, Woller SC, Moores L. Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. Chest. 2016 Feb;149(2):315-352. doi: 10.1016/j.chest.2015.11.026. Epub 2016 Jan 7. Erratum in: Chest. 2016 Oct;150(4):988.</citation>
    <PMID>26867832</PMID>
  </results_reference>
  <results_reference>
    <citation>Konstantinides SV, Meyer G, Becattini C, Bueno H, Geersing GJ, Harjola VP, Huisman MV, Humbert M, Jennings CS, Jiménez D, Kucher N, Lang IM, Lankeit M, Lorusso R, Mazzolai L, Meneveau N, Ní Áinle F, Prandoni P, Pruszczyk P, Righini M, Torbicki A, Van Belle E, Zamorano JL; ESC Scientific Document Group. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J. 2020 Jan 21;41(4):543-603. doi: 10.1093/eurheartj/ehz405.</citation>
    <PMID>31504429</PMID>
  </results_reference>
  <results_reference>
    <citation>Agnelli G, Buller HR, Cohen A, Gallus AS, Lee TC, Pak R, Raskob GE, Weitz JI, Yamabe T. Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial. J Thromb Haemost. 2015 Dec;13(12):2187-91. doi: 10.1111/jth.13153. Epub 2015 Oct 29.</citation>
    <PMID>26407753</PMID>
  </results_reference>
  <results_reference>
    <citation>McBane RD 2nd, Wysokinski WE, Le-Rademacher JG, Zemla T, Ashrani A, Tafur A, Perepu U, Anderson D, Gundabolu K, Kuzma C, Perez Botero J, Leon Ferre RA, Henkin S, Lenz CJ, Houghton DE, Vishnu P, Loprinzi CL. Apixaban and dalteparin in active malignancy-associated venous thromboembolism: The ADAM VTE trial. J Thromb Haemost. 2020 Feb;18(2):411-421. doi: 10.1111/jth.14662. Epub 2019 Nov 28.</citation>
    <PMID>31630479</PMID>
  </results_reference>
  <results_reference>
    <citation>Agnelli G, Becattini C, Bauersachs R, Brenner B, Campanini M, Cohen A, Connors JM, Fontanella A, Gussoni G, Huisman MV, Lambert C, Meyer G, Muñoz A, Abreu de Sousa J, Torbicki A, Verso M, Vescovo G; Caravaggio Study Investigators. Apixaban versus Dalteparin for the Treatment of Acute Venous Thromboembolism in Patients with Cancer: The Caravaggio Study. Thromb Haemost. 2018 Sep;118(9):1668-1678. doi: 10.1055/s-0038-1668523. Epub 2018 Aug 13.</citation>
    <PMID>30103252</PMID>
  </results_reference>
  <results_reference>
    <citation>Cheung KS, Leung WK. Gastrointestinal bleeding in patients on novel oral anticoagulants: Risk, prevention and management. World J Gastroenterol. 2017 Mar 21;23(11):1954-1963. doi: 10.3748/wjg.v23.i11.1954. Review.</citation>
    <PMID>28373761</PMID>
  </results_reference>
  <results_reference>
    <citation>Desai J, Kolb JM, Weitz JI, Aisenberg J. Gastrointestinal bleeding with the new oral anticoagulants--defining the issues and the management strategies. Thromb Haemost. 2013 Aug;110(2):205-12. doi: 10.1160/TH13-02-0150. Epub 2013 May 23. Review.</citation>
    <PMID>23702623</PMID>
  </results_reference>
  <results_reference>
    <citation>Desai J, Granger CB, Weitz JI, Aisenberg J. Novel oral anticoagulants in gastroenterology practice. Gastrointest Endosc. 2013 Aug;78(2):227-39. doi: 10.1016/j.gie.2013.04.179. Epub 2013 May 29. Review.</citation>
    <PMID>23725876</PMID>
  </results_reference>
  <results_reference>
    <citation>Cannon CP, Kohli P. Danger ahead: watch out for indirect comparisons! J Am Coll Cardiol. 2012 Aug 21;60(8):747-8. doi: 10.1016/j.jacc.2012.05.012.</citation>
    <PMID>22898071</PMID>
  </results_reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>June 29, 2020</study_first_submitted>
  <study_first_submitted_qc>July 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 8, 2020</study_first_posted>
  <last_update_submitted>July 3, 2020</last_update_submitted>
  <last_update_submitted_qc>July 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beni-Suef University</investigator_affiliation>
    <investigator_full_name>Mostafa El Mokadem</investigator_full_name>
    <investigator_title>Dr</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Venous Thrombosis</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Enoxaparin</mesh_term>
    <mesh_term>Apixaban</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

